Apellis Pharmaceuticals, Inc. Stock News

Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flo...

A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (APLS -5.99%) stock in the middle of the trading week. Investors didn't take this development well, and they collectively pushed down Apellis by almost 6%, on a day when the S&P 500 (^GSPC 0.43%) closed in the black with a 0.4% gain.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – ...

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) --  Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2025 financial results and business highlights.

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare Conference: Fireside chat on Tuesday, May 13, 2025 at 8:40 a.m.

WALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial results on Wednesday, May 7, 2025, at 8:30 a.m.

WALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Mr. Wheeler is a highly accomplished executive with more than 30 years of leadership experience across the biopharmaceutical industry.

PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membrano...